Key result
Slow-release quinidine bisulfate resulted in a lower average peak concentration and a delayed T-max (4 hr vs 2 hr) compared to conventional quinidine sulfate.
Why the study?
What are the disposition kinetics of conventional quinidine sulfate compared to slow-release quinidine bisulfate in normal subjects?
What are the disposition kinetics of conventional quinidine sulfate compared to slow-release quinidine bisulfate in normal subjects?
Answers are grounded in this paper and cite their sources.
Conventional quinidine sulfate produces higher peak serum concentrations and a shorter T-max compared to slow-release quinidine bisulfate, but both have similar clearance and can achieve similar steady-state concentrations with appropriate dosing.
There are relatively few studies on the disposition properties of quinidine. We have studied in 10 normal subjects conventional quinidine sulfate and a slow-release quinidine bisulfate. Single and repetitive doses were given; blood and urine concentrations were measured by the method of Cramer and Isaakson. After a single dose of two tablets of quinidine sulfate (400 mg), the average peak concentration was 2.13 +/-0.22 mug/ml (+/-SEM); following two tablets of the slow-release form, the average peak concentration was 1.17 +/-0.12 mug/ml. T-max was approximately 2 hr with quinidine sulfate and 4 hr with quinidine bisulfate. One fourth of both forms of the drug was recovered in the urine. Total body clearance was 0.36 L/kg-hr and renal clearance was 117 +/-22ml/min for both. With multiple dosing the serum quinidine concentration was higher than these predicted from the results of the single-dose study. Based on the mean estimates of quinidine half-life of 6 hr, a rapid method for achieving steady-state levels of quinidine would be to give an initial dose twice that of the maintenance dose. With the slow-release product if an equivalent dose was given every 12 hr, the mean steady-state quinidine serum concentration would be approximately the same.
No takes yet. Share an insight, caveat, or question.
Mahon et al. (1976) studied Healthy volunteers (n=10). Slow-release quinidine bisulfate vs. Conventional quinidine sulfate (400 mg) was evaluated on Average peak concentration (μg/ml). Slow-release quinidine bisulfate resulted in a lower average peak concentration and a delayed T-max (4 hr vs 2 hr) compared to conventional quinidine sulfate.
Synapse has enriched 10 related papers. Consider them for comparative context: